Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,935,984
  • Shares Outstanding, K 284,908
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,578 M
  • EBITDA $ 5,040 M
  • 60-Month Beta 0.25
  • Price/Sales 2.56
  • Price/Cash Flow 8.50
  • Price/Book 2.21

Options Overview Details

View History
  • Implied Volatility 24.04% (+2.11%)
  • Historical Volatility 21.10%
  • IV Percentile 49%
  • IV Rank 30.51%
  • IV High 40.49% on 04/10/25
  • IV Low 16.81% on 02/11/25
  • Expected Move (DTE 18) 6.57 (3.35%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 244
  • Volume Avg (30-Day) 1,499
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 25,623
  • Open Int (30-Day) 25,715
  • Expected Range 189.76 to 202.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.82
  • Number of Estimates 7
  • High Estimate 2.85
  • Low Estimate 2.79
  • Prior Year 3.43
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.52 +4.14%
on 12/09/25
202.75 -3.17%
on 12/12/25
+2.43 (+1.25%)
since 11/26/25
3-Month
162.29 +20.97%
on 11/06/25
202.75 -3.17%
on 12/12/25
+11.73 (+6.35%)
since 09/26/25
52-Week
162.29 +20.97%
on 11/06/25
251.99 -22.09%
on 02/03/25
-31.79 (-13.94%)
since 12/26/24

Most Recent Stories

More News
BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

BDX : 196.33 (+0.11%)
Is Solventum Stock Outperforming the Nasdaq?

Solventum has delivered stronger performance than the Nasdaq Composite over the past year, reinforcing analysts’ moderate optimism regarding the stock’s forward outlook.

SOLV : 80.46 (+0.35%)
$NASX : 23,593.10 (-0.09%)
BDX : 196.33 (+0.11%)
BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec

FRANKLIN LAKES, N.J. , Dec. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory...

BDX : 196.33 (+0.11%)
Baxter International Stock: Is BAX Underperforming the Health Care Sector?

Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.

XLV : 156.05 (+0.16%)
BDX : 196.33 (+0.11%)
BAX : 19.38 (+1.41%)
3 Reasons BDX is Risky and 1 Stock to Buy Instead

3 Reasons BDX is Risky and 1 Stock to Buy Instead

BDX : 196.33 (+0.11%)
BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories

FRANKLIN LAKES, N.J. , Dec. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ChemoGLO™, a specialist in hazardous drug detection...

BDX : 196.33 (+0.11%)
BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes

Three- and Four-Laser BD FACSDiscover™ A8 Cell Analyzers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis

BDX : 196.33 (+0.11%)
Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?

Becton, Dickinson and Company has notably underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

SOLV : 80.46 (+0.35%)
$NASX : 23,593.10 (-0.09%)
BDX : 196.33 (+0.11%)
BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

FRANKLIN LAKES, N.J. , Nov. 24, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™...

BDX : 196.33 (+0.11%)
1 Profitable Stock to Own for Decades and 2 We Avoid

1 Profitable Stock to Own for Decades and 2 We Avoid

PRIM : 129.16 (-0.29%)
BDX : 196.33 (+0.11%)
MAIN : 60.77 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 199.79
2nd Resistance Point 198.51
1st Resistance Point 197.42
Last Price 196.33
1st Support Level 195.06
2nd Support Level 193.78
3rd Support Level 192.69

See More

52-Week High 251.99
Fibonacci 61.8% 217.72
Fibonacci 50% 207.14
Fibonacci 38.2% 196.55
Last Price 196.33
52-Week Low 162.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar